LYRM2 and neoplasm: To determine the glucose metabolic reprogramming induced by LYRM2, which is critical for the increased tumour growth and metastasis, Hep3B and Huh7 cells with LYRM2 overexpressing were treated with 2‐deoxy‐d‐glucose (2‐DG), a known inhibitor of cellular glycolysis.